[ad_1]
In connection with the announcement of an interim result that the effectiveness of the new vaccine against coronavirus infection (Corona 19), which is being developed together with the American pharmaceutical company Pfizer and the German Bioentech, is more than 90% effective, Russian officials said on the 9th (local time) that their own country developed. One vaccine claimed to have similar effects.
According to the TASS news agency, Oksana Drafkina, director of the ‘National Center for Internal Medicine and Preventive Medicine’ under the Russian Ministry of Health, told reporters on the day: “We are observing the efficacy of the vaccination of the Sputnik V vaccine. ‘(a vaccine developed in Russia) in the public under the direction of the Ministry of Health. ” “As a result of observation, the efficacy is greater than 90%,” he said.
“The emergence of another effective vaccine is good news for everyone,” he said of Pfizer’s announcement of the efficacy of the vaccine.
Pfizer announced on the same day that analysis of 94 people infected with Corona 19 among participants in the phase 3 clinical trial showed that its vaccine was more than 90% effective in preventing Corona 19.
It was announced that it showed excellent efficacy that exceeded the expectations of the experts.
Until now, scientists had expected a corona19 vaccine with at least 75% effectiveness, CNBC reported.
Anthony Pouch, director of the National Institute of Allergy and Infectious Diseases, said a vaccine that is 50 to 60% effective is fine.
The Russian government previously approved (officially registered) the world’s first Sputnik V vaccine developed by the Gamalea National Center for Infectious Diseases and Microbiology, under its Ministry of Health, on August 11 and announced the achievements of its experts.
However, unlike conventional vaccine development procedures, Sputnik V bypassed phase 3 (Phase 3) clinical trials and gained national approval immediately after phases 1 and 2, raising concerns about efficacy and safety.
The Russian side later published the results of Phase 1 and 2 in the prestigious international medical journal ‘The Lancet’ and said: “Through two clinical trials conducted in June and July of this year, antibodies are formed from all participants And there are no serious side effects. It has been confirmed. “
Russia began vaccinating high-risk groups, such as medical staff and teachers, starting in September, and at the same time is conducting a “post-registration test”, which is practically the third phase, targeting some 40,000 citizens of Moscow.
Alexander Ginzburg, director of the Gamalea Center, said on the 7th that the production and supply of vaccines by Russian pharmaceutical companies continues to increase: “In the next two weeks, public vaccinations will begin in Moscow and Moscow.”
/ yunhap news
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution
